Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$894,000.

  • BridgeBio Pharma's Cash from Financing Activities fell 226.45% to -$894,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $835.4 million, marking a year-over-year increase of 209.41%. This contributed to the annual value of $748.5 million for FY2024, which is 65.76% up from last year.
  • Per BridgeBio Pharma's latest filing, its Cash from Financing Activities stood at -$894,000 for Q3 2025, which was down 100.30% from $302.0 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cash from Financing Activities registered a high of $547.9 million during Q1 2021, and its lowest value of -$135.5 million during Q3 2021.
  • For the 3-year period, BridgeBio Pharma's Cash from Financing Activities averaged around $142.0 million, with its median value being $60.3 million (2025).
  • Per our database at Business Quant, BridgeBio Pharma's Cash from Financing Activities crashed by 4,969.02% in 2021 and then soared by 94,005.62% in 2023.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Cash from Financing Activities stood at $325.4 million in 2021, then crashed by 98.04% to $6.4 million in 2022, then tumbled by 170.93% to -$4.5 million in 2023, then skyrocketed by 10,578.24% to $473.9 million in 2024, then plummeted by 226.45% to -$894,000 in 2025.
  • Its Cash from Financing Activities stands at -$894,000 for Q3 2025, versus $302.0 million for Q2 2025 and $60.3 million for Q1 2025.